CI
CRSP icon

Cordant Inc’s CRISPR Therapeutics CRSP Stock Holding History

Cordant Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546 Buy
+10
New +$527 ﹤0.01% 187
2025
Q2 		– Sell
-114
Closed -$3.88K – 75
2025
Q1 		$3.88K Buy
+114
New +$4.83K ﹤0.01% 81

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Cordant Inc's CRSP Position: Q2 2026 in Review

Cordant Inc opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10 shares worth $546. The stake represents ﹤0.01% of the portfolio and ranks #187 among its holdings. This is a return to the name: Cordant Inc previously reported a position in CRSP as recently as Q1 2025.

Cordant Inc first reported a position in CRSP in Q1 2025 and has held it in 2 quarters since. The position peaked at $3.88K in Q1 2025. 54 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Cordant Inc held 10 shares of CRISPR Therapeutics worth $546 as of Q2 2026.
  • CRISPR Therapeutics was a new Cordant Inc position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Cordant Inc's portfolio in Q2 2026, its #187 holding.
  • Cordant Inc first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Cordant Inc's CRISPR Therapeutics position peaked at $3.88K in Q1 2025.
  • 54 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Cordant Inc's 13F filing for Q2 2026, filed 15 Jul 2026.